Objective: To examine the effect of phosphate supplements on calcium homeostasis and bone turnover in young men. Design: Study 1 was a randomised, controlled, cross-over trial of 1000 mg elemental phosphate given for one week, with a standard diet of 800 mgad each of calcium and phosphorus. Study 2 was an escalating dose study of 0, 1000, 1500 and 2000 mgad elemental phosphate, each given for one week, with a standard diet of 1000 mgad each of calcium and phosphate. Setting: Northern General Hospital, Shef®eld. Subjects: Study 1, 10 healthy men ages 19±32 y. Study 2, 12 healthy men ages 19±38 y. Interventions: Sodium acid phosphate tablets each containing 500 mg elemental phosphorus (16.1 mmolad), given with meals. Results: Study 1, administration of 32.2 mmolad phosphorus resulted in a mean increase of 13.2 mmolad urinary phosphorus, a mean decrease of 1.1 mmolad urinary calcium, and a mean increase of 7 ngamL in serum intact PTH. There were no changes in serum phosphate, osteocalcin or urinary N-telopeptide excretion. Study 2, administration of 64.4 mmolad phosphorus resulted in a mean increase of 27.2 mmolad urinary phosphorus, a mean decrease of 2.4 mmolad urinary calcium, with no change in serum phosphate, PTH or urinary deoxypyridinoline. Conclusions: Phosphate supplementation of the diet does not affect bone turnover in young men.
Introduction
Although phosphate is an essential nutrient necessary for normal functioning, it has been suggested that relative to the amount of calcium ingested, phosphate is consumed in amounts that are too high for optimal bone health (Calvo & Park, 1996; Calvo, 1993) . Phosphate is present in most foods, but the diet also includes phosphate compounds such as polyphosphates which are added during the manufacturing of foods such as frozen poultry, bacon, processed cheeses, instant soups, desserts, sauces and carbonated beverages. Phosphates are used as pH regulators, emulsi®ers and anti-caking agents in order to reduce such problems as nutrient loss, fat oxidation and moisture migration. As a result of the growing use and consumption of phosphate-containing foods, individual phosphate intakes have increased over the past ten years, although it is not yet known whether these levels will have any signi®cant effects upon bone health (Gilbert et al, 1985) . The recommended ratio of calcium to phosphorus in the diet is 1:1 (on a molar basis) resulting in recommended values of 700 mgad of calcium and 550 mgad phosphorus for adults in the UK (Department of Health, 1991) . However, estimated daily intake of calcium and phosphorus in adult men in Britain is 900 and 1450 mgad, resulting in a molar ratio of 1.25 (Gregory et al, 1990) .
There is some support for an association between high phosphate to calcium ratios and an increased risk of osteoporosis. Forearm bone mineral content has been associated with an increase in this ratio (Tylavsky & Anderson, 1988; Lukert et al, 1987; Yano et al, 1985) . Radius BMC was related to phosphorus intake in premenopausal women (Metz et al, 1993) , but this may have been due to a confounding effect of protein intake (Barker et al, 1994) .
Administration of a diet high in phosphate and low in calcium has resulted in an increase in serum parathyroid hormone (Calvo et al, 1988) as has the administration of phosphate salts to young subjects (Silverberg et al, 1986) . The important question is whether these increases in parathyroid hormone levels result in increased bone resorption and hence accelerated bone loss.
There have been major advances in our ability to study bone resorption with the introduction of assays based on the pyridinium crosslinks of type I collagen such as deoxypyridinoline (speci®c to bone) or N-telopeptide crosslink of type I collagen. The present study was set up to use these new tools.
The study was designed in two parts. Firstly, to evaluate the effects of low and high phosphorus, subjects were given in random order these diets to evaluate their effect on bone turnover. Secondly, to evaluate the effects of extremes of phosphate intake, subjects were given escalating doses of phosphate. This approach was taken because phosphate supplements commonly cause diarrhoea, especially when introduced at high dose.
Methods
Study 1 Randomised crossover study A total of 10 healthy men ages 19±32 followed their usual diet for a week. Their habitual intake was assessed from a 7 d weighed diet diary. Each subject was provided with SOEHNLE electronic weighing scales with a range and accuracy of 0±2500 g and 2 g, respectively. They were provided with a food diary for dietary recording and given verbal tuition and written instructions on how to complete an accurate food diary and use the weighing scales. They were provided with information about recording foods when eating out of the house and for recording homemade recipes and retail foods. Food preferences were also obtained to enable the design of the test diet. The diaries were analysed using COMP-EAT (Nutritional Services Ltd, London, England).
Subjects were maintained on a dietary regimen for a two week period, which provided daily intakes of calcium of 800 mg and phosphate 800 mg. These intakes were achieved by providing subjects with evening meals and asking them to consume prescribed foods for breakfast, lunch and snacks. They were randomised to receive a phosphate supplement in the ®rst or the second of these two weeks. The supplement was 1000 mgad phosphorus given as two tablets of sodium acid phosphate 1.936 g, sodium bicarbonate 350 mg, and potassium bicarbonate 315 mg, equivalent to 16.1 mmol phosphate, 20.4 mmol sodium and 3.1 mmol potassium (Phosphate Sandoz, Sandoz Pharmaceuticals, Camberley, Surrey, England). The two tablets were taken in divided doses with meals.
Blood was taken 3 h after breakfast and two 24 h urine collections were made at the end of each week. The following measurements were made: serum calcium, serum phosphate, urine calcium, phosphate and creatinine (by standard autoanalyser methods) and serum intact PTH by immunoradiometric assay (Allegro intact PTH) and osteocalcin by radioimmunoassay (both from Nichols Institute, San Juan Capistrano, CA) and urine N-telopeptides of type I collagen (NTx) by ELISA (Ostex, Seattle, WA) and the results given in bone collagen equivalents (BCE) per day. All immunoassays were done in duplicate and the mean calculated.
Study 2 Escalating dose study
A total of 12 healthy men ages 19±38 y were maintained on their habitual phosphate intake for a week. The habitual intake was assessed from a 7 d weighed diet diary as above. They were then given food containing 1000 mgad calcium and phosphorus for four weeks. No supplement was given for the ®rst study week and then 1000, 1500, and 2000 mgad elemental phosphorus was given on each successive week, with the dose split between each of the three meals of the day. The supplement was the same as for study one.
Blood was taken before breakfast and two 24 h urine collections were made at the end of each week. The following measurements were made: serum calcium, serum phosphate, urine calcium, phosphate and creatinine (by standard autoanalyser methods) and serum intact PTH by immunoradiometric assay (Allegro intact PTH from Nichols Institute, San Juan Capistrano, CA). Urinary pyridinium crosslinks and were measured by HPLC after acid hydrolysis to allow measurement of total deoxypyridinoline (Colwell et al, 1993) . The assays for PTH and pyridinium crosslinks were done in duplicate and the mean calculated. No subjects in either protocol suffered from disease known to affect calcium metabolism. None were smokers and all were asked to abstain from alcohol during the protocols. Both protocols were approved by the Northern General Hospital Ethics Committee and all subjects gave written informed consent.
Statistics
In study 1, the biochemical data on the two diets were compared using the paired t-test. In study 2, the comparison was made using two-way analysis of variance (factors were subject and diet) using the Scheffe test for comparison between phosphate doses. A P-value of 0.05 was taken as signi®cant. Statistical analysis was performed using Statgraphics for Windows version 3 (Manugistics, Rockville, MD, USA).
Results

Study 1 Randomised crossover study
Nine subjects completed the protocol. From the 7 d weighed intake, the mean dietary calcium intake was estimated at 987 (223) mgaday (mean (s.d.)) and the major sources were milk, bread, cheese and yoghurt. The mean dietary phosphorus intake was 1538 (434) mgad and the major sources were milk, yoghurt, wholemeal bread, cheese, meats and tuna, and processed foods such as canned soups, dried pasta mix and baked beans.
The urinary phosphate was higher on the high phosphate diet (49.5, 11.6 mmolad) than on the low phosphate diet (34.3, 8.3, P`0.001) (Figure 1 ). The urinary calcium was lower on the high phosphate diet (4.4, 1.2 mmolad) than on the low phosphate diet (5.5, 1.3, P`0.05). The intact PTH was higher on the high phosphate diet (33.7, 11.7 ngamL) than on the low phosphate diet (26.7, 10.9, P`0.01). The serum phosphate did not differ on the high phosphate diet (1.38, 0.17 mmolaL) as compared to the low phosphate diet (1.35, 0.16). The serum calcium did not differ on the high phosphate diet (2.37, 0.06 mmolaL) as compared to the low phosphate diet (2.40, 0.05).
The serum osteocalcin did not differ on the high phosphate diet (7.0, 1.4 ngamL) as compared to the low phosphate diet (6.6, 1.5). The urinary excretion of NTx did not differ on the high phosphate diet (532, 257 nmol BCEad) as compared to the low phosphate diet (540, 267).
Study 2 Escalating dose study
A total of eleven of the twelve subjects completed the protocol successfully. One volunteer completed the study up to the 1500 mgad dose, but developed diarrhoea on the 2000 mgad dose and so his results from this last period were not used. Body weight over the study did not change signi®cantly. The tablets were counted at the end of the study and compliance was above 90% in all cases.
There were signi®cant changes in urinary phosphate and calcium (Figure 2 ). The urinary phosphate was higher on the highest phosphate diet (61.4, 13.2 mmolad) than on the lowest phosphate diet (34.2, 12.4) (Figure 2 ). The urinary calcium was lower on the highest phosphate diet (2.5, Changes in urinary phosphate, calcium and serum intact PTH in response to low (800 mgad) and high (1800 mgad) phosphate intakes in Study 1. There was an increase in urinary phosphate (P`0.001, paired t test), a decrease in urinary calcium (P`0.05), and an increase in PTH (P`0.01).
Figure 2 Changes in urinary phosphate and calcium in response to escalating doses of phosphate (1000±3000 mgad) in Study 2. There was an increase in urinary phosphate (P`0.001, ANOVA) and a decrease in urinary calcium (P`0.001). The thick line represents the mean and the error bars, the standard error of the mean. Time points that did not differ (at P`0.05) have the same letter (Scheffe test), namely urinary phosphate excretion was increased and urinary calcium decreased compared to baseline after increasing the dose to 2500 and 3000 mgad. There was no signi®cant change in either measurement. The thick line represents the mean and the error bars, the standard error of the mean.
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Discussion
Both of these studies showed an increase in urinary excretion of phosphate and a decrease in urinary calcium. The increase in urinary phosphate equivalent to about half of the administered dose is to be expected (Bell et al, 1977; Van Den Berg et al, 1980) as the fractional absorption of phosphate is about 50%. The decrease in urinary calcium is a result of decreased calcium absorption and an increase in endogenous faecal calcium (Heaney & Recker, 1982) . The decrease in calcium absorption results from a decrease in the active form of vitamin D, calcitriol (Portale et al. 1986; Van Den Berg et al, 1980) . Serum phosphate is an important regulator of 1-alpha hydroxylase in the kidney. Although the serum phosphorus at a single time point did not increase with phosphate supplements, it is likely that we would have found it to be increased had we included a circadian rhythm study of serum phosphorus in our protocol (as did Calvo et al, 1988) .
The serum intact PTH increased in the ®rst study by a mean of 26% and this is in keeping with the effect of high phosphate (low calcium) diets in young men (Calvo et al, 1988) and with the effect of phosphate supplementation (Silverberg et al, 1986) . The effect of phosphate appears to be greater in women than in men (Calvo et al, 1988) and in older compared to younger women (Silverberg et al, 1989) . There was no effect of phosphate on PTH in the second study. This was most likely due to the timing of the blood sampling, other studies have shown higher levels of serum phosphate and PTH after a meal (Calvo et al, 1990; Calvo et al, 1988; Portale et al, 1989) . The dose of phosphate used in the second study was high, and was above the 2.5th percentile reported for British men of 2310 mgad (Gregory et al, 1990) .
There was no change in bone resorption markers in either study. The NTx assay is clearly increased in primary hyperparathyroidism and returns to normal with effective treatment (Guo et al, 1996) . Total deoxypyridinoline is the gold standard of bone resorption markers in that it is speci®c to bone, correlates well with estimates of bone resorption by calcium kinetics (Eastell et al, 1997) and is not affected by renal metabolism, unlike other crosslink forms (Colwell & Eastell, 1996) . Previous studies have reported no change in free deoxypyridinoline (Karkkainen & Lamberg-Allardt, 1996) and no change (Zemel & Linkswiler, 1981; Calvo et al, 1990; Silverberg et al, 1986) or an increase in urinary hydroxyproline (Calvo et al, 1988; Bell et al, 1977) . Hydroxyproline is a poor marker of bone resorption and is affected by the collagen composition of the diet (Colwell et al, 1993 ).
An increase in PTH would be expected to increase bone resorption. For example, Cosman et al (1991) reported an increase in collagen crosslinks shortly after starting an infusion of PTH. It may be that the increase in serum phosphorus antagonises the effect of PTH on bone resorption. In organ culture experiments it has been shown that the phosphate concentration modulates bone resorption. A high media phosphate inhibits bone resorption. For example, Yates et al (1991) reported that a high phosphate medium decreased production of new osteoclasts from their precursors (mouse bone marrow culture) and decreased bone resorption by mature osteoclasts (chicken and rat osteoclasts on dentine slices).
Phosphorus is present in a wider range of foods than calcium and it is added to food (usually as a polyphosphate) and to cola drinks (as phosphoric acid). The different forms in which phosphorus is present in the diet may have differing effects on calcium homeostasis (Zemel & Linkswiler, 1981) . Orthophosphate administration may not cause bone loss. In balance experiments, orthophosphate did not have the adverse effects of polyphosphate (Zemel & Linkswiler, 1981) . In the treatment of postmenopausal osteoporosis, orthophosphate given along with etidronate had no adverse (or bene®cial) effect (Watts et al, 1990) . In a small group of women with osteoporosis calcium balance and radius BMD improved with orthophosphate therapy (Goldsmith et al, 1976) . If the present study had been conducted with polyphosphates, the outcome could have differed.
Conclusions
It is likely that changing from a low to a high dietary phosphate diet has little effect on bone turnover in young men and so is unlikely to affect bone mass at maturity. It remains an open question as to whether it is an important determinant of peak bone mass in women or has an effect on bone loss in older women.
